HomeComparePROC vs PLD

PROC vs PLD: Dividend Comparison 2026

PROC yields 198.02% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROC wins by $106.19M in total portfolio value
10 years
PROC
PROC
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full PROC calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — PROC vs PLD

📍 PROC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROCPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROC + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROC pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROC
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PROC beats the other by $43,586,353.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROC + PLD for your $10,000?

PROC: 50%PLD: 50%
100% PLD50/50100% PROC
Portfolio after 10yr
$59.60M
Annual income
$30,895,467.91/yr
Blended yield
51.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

PROC
Analyst Ratings
1
Hold
Consensus: Hold
Price Target
$10.00
+890.1% upside vs current
Range: $10.00 — $10.00
Altman Z
0.9
Piotroski
5/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROC buys
0
PLD buys
0
No recent congressional trades found for PROC or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROCPLD
Forward yield198.02%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$112.70M$6.50M
Annual income after 10y$56,534,499.65$5,256,436.18
Total dividends collected$106.15M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$10.00$136.00

Year-by-year: PROC vs PLD ($10,000, DRIP)

YearPROC PortfolioPROC Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$30,502$19,801.98$11,255$555.24+$19.2KPROC
2$89,086$56,448.56$13,062$1,018.59+$76.0KPROC
3$249,403$154,080.96$15,903$1,926.67+$233.5KPROC
4$670,003$403,142.26$20,839$3,823.32+$649.2KPROC
5$1,729,066$1,012,162.66$30,464$8,166.08+$1.70MPROC
6$4,291,289$2,441,188.37$52,054$19,457.30+$4.24MPROC
7$10,253,990$5,662,310.92$109,886$54,188.93+$10.14MPROC
8$23,616,660$12,644,890.45$304,030$186,451.18+$23.31MPROC
9$52,487,868$27,218,041.68$1,166,125$840,813.32+$51.32MPROC
10$112,696,518$56,534,499.65$6,504,190$5,256,436.18+$106.19MPROC

PROC vs PLD: Complete Analysis 2026

PROCStock

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Full PROC Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this PROC vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROC vs SCHDPROC vs JEPIPROC vs OPROC vs KOPROC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.